The United Kingdom and the United States have agreed to a key bilateral deal that will preserve no duties on British drug shipments being sold in the American market.
Key Provisions of the Accord
Under the terms of the agreement, the UK has pledged to increase expenditure on pharmaceuticals through the NHS. This commitment guarantees that duties on these key goods will remain at zero for a timeframe of 36 months.
This deal is in response to recent threats to hike tariffs on patented drug products, with potential rates floated up to 100%.
"This arrangement between the Britain reinforces the global environment for innovative medicines and establishes much-needed equity to U.S.–U.K. pharmaceutical trade," an announcement noted.
Economic Significance
Pharmaceuticals are one of the Britain's biggest export categories to the US, which is by far the biggest buyer for major UK drugmakers.
Export figures show that in the year prior to last September, the UK sold drugs worth over eleven billion pounds to the US. This value made up nearly one-fifth of all goods exports in that span.
"This guarantee safeguards employment, increases capital expenditure and paves the way for the UK to establish itself as a worldwide center for medical research," the Business and Trade Secretary stated.
Key British Pledges
The deal involves several key pledges from the British government:
- Revised Affordability Limit: The UK will lift the cost ceiling at which it judges new treatments to be unaffordable by 25%.
- Boosted Medicine Funding: There is a target to raise total NHS spending on medicines from 0.3% of Gross Domestic Product to 0.6% over the following ten-year period.
- Refund Ceiling: The percentage pharmaceutical firms must return to the NHS to prevent overspending will be capped at fifteen percent. Previously, rebates topped twenty percent.
Industry Background
The deal comes amid a ongoing row between the drug companies and the UK government over drug pricing and approval rates.
These tensions were heightened by assertions that American customers were charged a premium for the identical medicines than patients in the other developed nations.
Recently, several major drug company projects in the UK have been paused or scrapped, while major investments have been pledged toward US facilities.
One official publicly accepted that the NHS had to invest a greater share on medicines, noting that its spending on drugs had decreased as a share of its resources over the last ten years.
